Standards for assessing and reporting adverse events
- PMID: 36375481
- DOI: 10.1016/S2213-2600(22)00444-1
Standards for assessing and reporting adverse events
Conflict of interest statement
HM declares grants from Bayer Yakuhin, Actelion Pharmaceuticals Japan, GlaxoSmithKline, Mochida Pharmaceutical, Janssen Pharmaceuticals, and Reata Pharmaceuticals; and personal fees from Actelion Pharmaceuticals Japan, Kaneka Medix, GlaxoSmithKline, Nippon Shinyaku, Bayer Yakuhin, Pfizer, Sumitomo Dainippon Pharma, Mochida Pharmaceutical, Janssen Pharmaceuticals, TOA EIYO, Viatris, and MSD. Declarations for the other authors remain the same as in the original Article. Arata Yoneda (EviPRO) provided medical writing support; the authors of the manuscript covered the fee for this support at their own expense. TK and HM contributed equally to this Correspondence.
Comment on
-
Medical and interventional therapies for inoperable CTEPH: a necessary combination?Lancet Respir Med. 2022 Oct;10(10):926-927. doi: 10.1016/S2213-2600(22)00227-2. Epub 2022 Aug 1. Lancet Respir Med. 2022. PMID: 35926545 No abstract available.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
